Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Odyssey Therapeutics

Request full access

Building a machine learning-based platform to develop novel therapeutics focusing on cancer and autoimmune diseases

Boston, United StatesFounded 2018Biotech & Life Sciences

About Odyssey Therapeutics

Odyssey Therapeutics, Inc. operates as a biotechnology company focused on developing next-generation precision immunomodulators and oncology medicines. The firm was founded in 2021 by Gary D. Glick, Ph.D., a serial biotech entrepreneur with a background in chemistry and a track record of founding successful companies like Lycera, IFM Therapeutics, and Scorpion Therapeutics. Glick's journey began as a chemistry professor at the University of Michigan before he transitioned into the biotech industry, driven by a problem-first approach to drug discovery rather than focusing on a specific technology.

The company's business is centered on creating a sustainable pipeline of therapeutics for cancer and inflammatory diseases affecting large patient populations. Odyssey has established a highly integrated drug discovery engine that combines advanced computational tools, including artificial intelligence and machine learning, with deep expertise in chemistry and biology to tackle challenging drug targets. This engine is designed to accelerate the identification and development of both small-molecule and protein-based therapies. The company's revenue model is predicated on the successful development and commercialization of its product candidates, which involves substantial investment in research and development funded by significant venture capital.

Odyssey's discovery platform is a key differentiator, integrating physics-based molecular simulations, AI, and machine learning to unlock high-value targets, some of which were previously considered undruggable. In a strategic move to bolster these capabilities, the company acquired Rahko, a quantum machine learning company, in January 2022. This acquisition integrated a platform that uses computational chemistry, machine learning, and quantum computing to better simulate drug behavior and identify novel binding sites. Odyssey's pipeline includes multiple preclinical programs in immunology and oncology. The company has raised substantial capital to advance these programs toward clinical trials, securing a $218 million Series A in December 2021, a $168 million Series B in October 2022, and a $101 million Series C in December 2023, bringing its total funding to nearly $500 million within its first few years.

Source: Dealroom company data

At a glance

Status
Operational
Employees
122
Open positions
None listed
Dealroom signal
65.4/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology, Health Platform
Sector
Biotechnology, Oncology, Drug Development, Core AI, Precision Medicine
Technology
Artificial Intelligence, Deep Tech, Machine Learning
Business model
SaaS
Client focus
B2B
Investment activity
2 companies, latest Dec 2021
Capital deployed
—
Preferred round
ACQUISITION

Funding history

7 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
IPOOther financing May 2026 $279M $810M Cowen Group · Cantor Fitzgerald · JP Morgan ↗
SERIES DOther financing Sep 2025 $213M $852M Jeito Capital · Affinity Asset Advisors · Lightspeed Venture Partners · TPG ↗
Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

Odyssey Therapeutics website traffic

Latest recorded traffic for Odyssey Therapeutics is 7.7K monthly website visits, up 48.1% over the last three months. Odyssey Therapeutics's team grew 3.4% over the past year.

Latest monthly visits7.7K 3-month web change+48.1% 1-year team growth+3.4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Odyssey Therapeutics in the Boston ecosystem

Live from Dealroom

The Odyssey Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

33 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A16 investors entered at this stage

Series B and later13 investors entered at this stage

  • Ascenta Capital
  • Leerink Partners
  • BlackMars Capital
  • Racing Beach Ventures
  • KB Investment
  • AB Magnitude Ventures
  • Global BioAccess Fund
  • Jeito Capital
  • Affinity Asset Advisors
  • Lightspeed Venture Partners
  • TPG
  • Dimension
  • Wedbush Healthcare Partners

Other known investors4 additional known investors

  • Cantor Fitzgerald
  • Cowen Group
  • JP Morgan
  • University of Bonn
Team profiled 17 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
7 countries with
team presence
🇺🇸 United States84%
🇩🇪 Germany11.3%
🇬🇷 Greece0.9%
🇦🇺 Australia0.9%
🇮🇳 India0.9%
Top 5 of 7 shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Odyssey Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Odyssey Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.